2025-11-30 - Analysis Report
Okay, let's break down the analysis of Hims & Hers Health Inc. (HIMS).

**0) Overview:**

*   **Ticker:** HIMS
*   **Company:** Hims & Hers Health Inc. - A telehealth company focused on providing personalized health and wellness solutions directly to consumers.

**1) Return Rate Comparison (vs. S&P 500 - VOO):**

*   **HIMS Cumulative Return:** 158.66%
*   **VOO Cumulative Return:** 75.88%
*   **Divergence:** 57.2
*   **Relative Divergence:** 35.2

**Analysis of Alpha, Beta, CAGR, MDD:**

The table shows performance metrics for rolling 3-year periods.

|            Year |   CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|-----------------:|-------:|------:|--------:|-------:|---------:|
|       2019-2021 |   -42  |  74.4 |   -81   |    0   |      1.5 |
|       2020-2022 |   -19  |  78.6 |   -18   |   -0   |      1.5 |
|       2021-2023 |   -65  |  78.6 |   -67   |   -0.1 |      2   |
|       2022-2024 |   119  |  79.4 |    98   |   -0   |      5.5 |
|       2023-2025 |   163  |  80.8 |    97   |    0.1 |      9.1 |

*   **CAGR:**  The Compound Annual Growth Rate has fluctuated significantly.  The recent period (2023-2025) shows a strong positive CAGR of 163%, following several periods of negative growth.
*   **MDD:**  The Maximum Drawdown (MDD) is consistently high, around 75-80%, indicating significant volatility and potential risk of large losses.
*   **Alpha:** Alpha represents the outperformance relative to a benchmark (presumably the S&P 500).  Negative Alpha values in earlier periods suggest underperformance, while the recent period (2022-2025, 2023-2025) shows a high positive Alpha, indicating strong outperformance.
*   **Beta:** Beta measures the stock's volatility relative to the market. Beta values close to zero suggests that HIMS's price is not closely correlated with the overall market (S&P500).
*   **Cap(B):** Market capitalization has grown significantly over the periods, from 1.5B to 9.1B.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 39.76
*   **Last Market Data:** Price=39.76, Previous Close=38.4, Change=3.54
*   **5-day SMA:** 37.55
*   **20-day SMA:** 39.13
*   **60-day SMA:** 48.40

**Analysis:** The stock price is above its 5-day and 20-day moving averages, suggesting short-term upward momentum. However, the price is significantly below its 60-day moving average, indicating a possible longer-term downtrend (or recovery from a larger dip). The most recent price change of 3.54 indicates a strong upward movement in the last trading session.

**3) RSI, PPO, and Market Risk Indicators:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 46.51 (Neutral - neither overbought nor oversold)
*   **PPO:** 1.24 (Positive - Short-term moving average is above the long-term moving average, indicating an uptrend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** -2.6 (short-term decline)
*   **Expected Return:** 21.4% (Long-term, vs. S&P 500)

**Analysis:**

*   The MRI suggests the investment is considered a Medium Investment.
*   The RSI of 46.51 is considered neutral.
*   PPO is positive, suggesting a possible uptrend.
*   The hybrid signal suggests buying 100% with cash.
*   The recent decrease in relative divergence shows a short-term decrease.

**4) Recent News & Significant Events:**

*   **Positive:**
    *   HIMS stock rose 14% this week.
    *   $250 Million Share Repurchase Program Authorization.
    *   Revenue Continues to Surge.
*   **Negative:**
    *   Hims & Hers Health (HIMS) Is Down 7.6% After Narrowing 2025 Revenue Guidance and Q3 Results.

**Analysis:** Recent news presents a mixed picture.  The share repurchase program and rising revenue are positive signals. However, the narrowing of revenue guidance and subsequent price drop highlight some concerns about future growth prospects.

**4-2) Analyst Opinions:**

*   **Consensus:** Hold (Mean: 2.86)
*   **Target Price:** Avg: $46.00 / High: $85.00 / Low: $25.00

**Analysis:**  The consensus "Hold" rating suggests analysts are not overwhelmingly bullish or bearish on the stock. The average target price of $46.00 indicates a potential upside from the current price. The wide range between the high and low target prices ($25.00-$85.00) shows significant uncertainty in analysts' expectations.

**5) Recent Earnings Analysis:**

| Date       |   EPS |   Revenue |
|------------|------:|----------:|
| 2025-11-03 |  0.07 | 0.60 B$   |
| 2025-08-04 |  0.19 | 0.54 B$   |
| 2025-05-05 |  0.22 | 0.59 B$   |
| 2024-11-04 |  0.35 | 0.40 B$   |
| 2025-11-03 |  0.35 | 0.40 B$   |

**Analysis:** Revenue has been generally increasing quarter by quarter, however EPS has fluctuated.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin   |
|------------|-----------|-----------------|
| 2025-09-30 | \$0.60B  | 73.80%         |
| 2025-06-30 | \$0.54B  | 76.39%         |
| 2025-03-31 | \$0.59B  | 73.50%         |
| 2024-12-31 | \$0.48B  | 76.81%         |
| 2024-09-30 | \$0.40B  | 79.16%         |

**Capital and Profitability:**

| Quarter    | Equity    | ROE   |
|------------|-----------|-------|
| 2025-09-30 | \$0.58B  | 2.72% |
| 2025-06-30 | \$0.56B  | 7.55% |
| 2025-03-31 | \$0.55B  | 9.01% |
| 2024-12-31 | \$0.48B  | 5.46% |
| 2024-09-30 | \$0.44B  | 17.18% |

**Analysis:**

*   **Revenue:**  Revenue is showing a clear upward trend.
*   **Profit Margin:** Profit margins are consistently high (above 70%), indicating strong profitability.
*   **Equity:** Equity is gradually increasing.
*   **ROE:** Return on Equity (ROE) has fluctuated.

**7) Comprehensive Analysis (Summary):**

HIMS presents a mixed picture.

*   **Strengths:** High revenue growth, strong profit margins, recent positive price momentum, potential long-term outperformance (based on expected return), and a share repurchase program.
*   **Weaknesses:** High volatility (MDD), mixed analyst ratings (hold), uncertainties related to future growth guidance, fluctuation in EPS, and concerns about the long-term sustainability of its business model.

**Overall Recommendation:**

Given the high volatility, and mixed signals, a cautious approach is advised.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.